Biomarkers for Oncology
JH · Effective Oct 1, 2015
148 active Medicare policies list C48.8, and 8 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
Showing 100 of 148
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
8 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C48.8 |
|---|---|---|
| Cancer Antigen 125 Testing | Oct 1, 2026 | Covered |
| Cancer Antigen 19-9 Testing | Oct 1, 2026 | Covered |
| Carcinoembryonic Antigen Testing | Oct 1, 2026 | Covered |
| Human Chorionic Gonadotropin Testing | Apr 15, 2026 | Covered |
| Outpatient Alpha-Fetoprotein Testing | Apr 15, 2026 | Covered |
JF · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J6 · Effective Jul 15, 2026
JK · Effective Jul 15, 2026
JJ · Effective Jul 24, 2022
JM · Effective Jul 24, 2022
J15 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J6 · Effective Apr 1, 2019
JK · Effective Apr 1, 2019
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Feb 19, 2023
JM · Effective Feb 19, 2023
J15 · Effective Aug 21, 2022
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Feb 10, 2020
JE · Effective May 17, 2020
JF · Effective May 17, 2020
JJ · Effective Feb 10, 2020
JM · Effective Feb 10, 2020
J5 · Effective Feb 9, 2020
J8 · Effective Feb 9, 2020
J15 · Effective Jul 27, 2020
JE · Effective Dec 26, 2022
JF · Effective Dec 26, 2022
JJ · Effective Feb 3, 2020
JM · Effective Feb 3, 2020
J5 · Effective Mar 15, 2020
J8 · Effective Mar 15, 2020
JE · Effective Oct 8, 2018
JF · Effective Oct 8, 2018
J9 · Effective Oct 1, 2015
J6 · Effective May 1, 2017
JK · Effective May 1, 2017
J15 · Effective Oct 24, 2016
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JJ · Effective Dec 3, 2023
JM · Effective Dec 3, 2023
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Nov 12, 2023
JM · Effective Nov 12, 2023
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JJ · Effective Jun 12, 2017
JM · Effective Jun 12, 2017
J6 · Effective Apr 1, 2026
J6 · Effective Jul 1, 2026
JL · Effective Apr 24, 2025
National · Effective Oct 1, 2025
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Nov 6, 2025
National · Effective Oct 1, 2026
National · Effective Jul 15, 2026
National · Effective Sep 27, 2026
National · Effective Mar 5, 2026
J6 · Effective Oct 1, 2026
National · Effective Nov 16, 2023
| Policy | Effective | Status of C48.8 |
|---|
| Bevacizumab for Non-Ocular Indications | Feb 20, 2024 | Covered |
|---|---|---|
| Hyperthermia in Cancer Therapy | Feb 9, 2024 | Covered |
| Pharmacogenetic and Pharmacodynamic Testing | Feb 27, 2024 | Covered |